There is no consensus about the treatment of diabetic bone disorder. However, the improvement of glycemic control has been suggested to have a beneficial effect on bone in T1D. Recently, several experiments showed promising results on using anabolic pharmacological agents in diabetic rodents with bone disorder. Therefore, randomized clinical trials are needed to test the possible use of the bone anabolic therapies in humans with T1D.

The article presents the results of our own studies of clinical, anamnestic and laboratory parameters in patients with severe COVID-19. The aim of the study was to identify possible clinical and laboratory predictors of an unfavorable out-come of a severe course of Covid-19 in patients with diabetes mellitus and hy-perglycemia. A retrospective analysis of data from primary medical records of 320 patients was performed. All patients received medical care in the intensive care unit of the infectious hospital in Minsk from June 2020 to March 2022. Based on the results of the assessment of glycemic parameters, all patients were divided into the following groups: 224 people with hospital hyperglycemia (HH), 51 patients with a history of diabetes mellitus (DM) and/or newly diagnosed and 45 people without glycemic disorders. Covid-19 infection confirmed by a positive PCR or antigen test from respiratory swabs. Patients with HH and DM had high-er levels of ESR, procalcitonin, CRP, LDH, neutrophils, more pronounced lym-phopenia, which indicated a more pronounced inflammatory process. The level of D-dimers was assessed as a biomarker of the coagulopathy process, it was al-so higher in the groups of patients with DM and HH. According to the results of the study, 70 % of patients with severe COVID-19 had newly diagnosed hyper-glycemia, and from day 4, patients with an unfavorable outcome showed a ten-dency to persistent hyperglycemia, which potentially indicates its role as a prog-nostic parameter.

BACKGROUND AND AIM: Currently relationship between the decrease in vitamin D (VD) levels and the formation of bone pathology has established. The presence of certain vitamin D receptor (VDR) polymorphisms has been suggested to be associated with the serum vitamin D. Therefore, the aim of study was to assess the association between VDR single nucleotide polymorphisms (SNPs) in type 1 diabetic patients and serum VD.

Osteoporosis is a common skeletal disease characterized by low bone mass and microarchitectural deterioration with increased susceptibility to fracture. Osteoporosis has a complex etiology and is considered to be a multifactorial polygenic disease. Low bone mineral density (BMD) and fracture risk are associated with type 1 diabetes (T1D). There are more than 150 genes associated with bone mineral density. Vitamin D receptor (VDR) polymorphisms have been suggested to be associated with the diabetic complications. Our aim was to investigate the frequency of occurrence of vitamin D receptor (VDR)-(FokI, BsmI, ApaI, TaqI)-single nucleotide polymorphisms (SNPs) in type 1 diabetic patients.

No abstract